ABSTRACT -One of the toxicities caused by 1-Methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) is damage to dopaminergic neurons. When injected into C57BL/6J mice, MPTP penetrates into the brain and is converted to 1-methyl-4-phenylpyridinium (MPP + ) by monoamine oxidase (MAO)-B in astrocytes. MPP + has high affinity for the dopamine transporter (DAT) on dopaminergic neurons, and is taken up into the cell to cause cell death. There have been relatively few researches on the acute MPTP toxicity to embryonic or newborn mice. In the present study, we attempted to evaluate the influence of MPTP and MPP + on embryonic and newborn mice by measuring sequential changes in major indexes of MPTP toxicity and MPTP metabolism; levels of Tyrosine Hydroxylase (TH), DAT, MAO-A and MAO-B. In addition, we measured the levels of dopamine and its metabolites, 3,4-dihydroxy-phenylacetic acid (DOPAC) and homovanillic acid (HVA), in the brain of newborn mice. A single injection of MPTP and MPP + reduced the levels of dopamine and its metabolites, DOPAC and HVA, in the brain of newborn mice about 6-12 hr after the injection. Similarly the levels of mRNAs and proteins of DAT and TH were lowered in the brain of embryonic and newborn mice as well. The levels of these indexes were generally recovered at 24 hr after injection, indicating that the neurotoxicity induced by a single injection of MPTP or MPP + is temporary and recoverable in embryonic and newborn mice. By contrast, no significant changes in the expression levels of MAO-A and MAO-B were observed in either MPTP-or MPP + -treated mice.
INTRODUCTION
1-Methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP), a byproduct of the chemical synthesis of desmethylprodine, is an opioid analgesic with a heroinlike effect (Johannessen and Markey, 1984; Riederer et al., 2002; Vanitallie, 2008) . The damage to dopaminergic neurons in the nigrostriatal system caused by MPTP is very similar to that seen in idiopathic Parkinson disease (PD) (Mandel et al., 2007; Yokoyama et al., 2008) . C57BL/6J mice (Eldad et al., 1990; Teismann et al., 2001; Xiao et al., 2004; Smeyne et al., 2005; He et al., 2008b) and several species of primates (Jenner, 2009; Johnston et al., 2010) sensitive to MPTP are currently used as animal models for idiopathic PD (Schapira et al., 2007) . When injected into these animals, MPTP penetrates the blood-brain barrier (BBB) and is converted to 1-methyl-4-phenylpyridinium (MPP + ) by monoamine oxidase-B (MAO-B) in astrocytes (Levitt et al., 1982; Singer et al., 1986; Di Monte et al., 1992; O'Callaghan and Seidler, 1992; Ghosh et al., 2007; Chen et al., 2008; He et al., 2008a; Sonsalla et al., 2010) . MPP + has high affinity for the dopamine transporter (DAT) on dopaminergic cells (Javitch and Snyder, 1984; Chiba et al., 1985; Lotharius and O'Malley, 2000; Obata et al., 2006) , and is taken up into the cell (Reinhard et al., 1987; Daniels and Reinhard, 1988; Del Zompo et al., 1993; Obata et al., 2006) , where it accumulates in the mitochondria and causes neuronal cell death (Muñoz et al., 2006; Seo et al., 2006; Schapira et al., 2007) .
There have been many studies on the neurotoxicity of MPTP in adult mice (He et al., 2008a (He et al., , 2008b Shibui et al., 2009; Berry et al., 2010; Dehay et al., 2010; Ito et al., 2012 Ito et al., , 2013a Ito et al., and 2013b , but relatively few on that in embryonic and newborn mice. Chronic exposure to MPTP during organogenesis (days 6 to 15 of gestation (GD 6 to 15)) reduced fetal weight, motor activity, numbers of striatal tyrosine hydroxylase (TH)-positive cells, and amounts of dopamine and homovanillic acid (HVA) (Wolfgang and Beat, 1991) . By contrast, fetal mice treated once with MPTP at GD17 showed unchanged dopamine concentrations in the brain 24 hr after birth and in the striatum 14 and 28 days after birth (Melamed et al., 1990) . These studies used postnatal mice prenatally exposed to MPTP or an MPTP metabolite, MPP + . However, acute MPTP toxicity in embryonic or newborn mice has not been investigated.
In the present study, we attempted to evaluate the influence of MPTP or MPP + on embryonic and newborn mice by measuring sequential changes in major indexes of MPTP toxicity and MPTP metabolism; levels of TH, DAT, MAO-A and MAO-B. In addition, we measured the levels of dopamine and its metabolites, 3,4-dihydroxyphenylacetic acid (DOPAC) and HVA, in the midbrain and striatum of newborn mice to verify the influence of MPTP and MPP + on the function of the dopamine system.
MATERIALS AND METHODS

Animals
Pregnant day (PD) 11 and 8-day-old (with their mother) C57BL/6 mice were obtained from Charles River Japan (Kanagawa, Japan). They were housed in metal cages under controlled conditions (temperature, 23 ± 2°C; relative humidity, 55 ± 5%; light/dark cycle, 12/12 hr) using an isolator caging system (Niki Shoji, Tokyo, Japan), and fed commercial pellets (MF; Oriental Yeast., Tokyo, Japan) and water ad libitum. All procedures used in the present study were approved by the Committee of Animal Experiments of the Graduate School of Agricultural and Life Sciences, the University of Tokyo.
Drug injection
MPTP-HCl (Sigma, St. Louis, MO, USA) and MPPIodide (Sigma) were dissolved in saline. Four PD 12 pregnant mice and 6 (3 males and 3 females) 9-day-old newborn mice were injected i.p. with 25.0 mg/kg MPTPHCl or 17.1 mg/kg MPP-Iodide. In the preliminary study, pregnant mice at PD 12 were injected i.p. with 12.5, 25.0 or 50.0 mg/kg MPTP-HCl (2 mice, respectively) or 8.6, 17.1 or 34.2 mg/kg MPP-Iodide (2 mice, respectively). The majority of 50.0 mg/kg MPTP-HCl-or 34.2 mg/kg MPP-Iodide-treated mice at PD 12 were died (1 of 2 mice and 2 of 2 mice, respectively), and no changes of performance status were observed in the 12.5 mg/kg MPTPHCl-or 8.6 mg/kg MPP-Iodide-treated mice at PD 12 (1 of 2 mice and 2 of 2 mice, respectively). Hence we decided the injection dose of MPTP-HCl and MPP-Iodide as 25.0 and 17.1 mg/kg, respectively. As a control, the same number of corresponding mice were i.p. injected with an equivalent volume of saline (10.0 ml/kg). At 6, 12 and 24 hr after treatment, mice were sacrificed by exsanguination under a deep anesthesia with diethylether.
Total mRNA extraction and RT-PCR analysis
For total mRNA extraction, 2 to 3 cephalic parts of embryos per dam or the left half of the midbrain and the striatum of newborn mice were homogenized in ISOGEN fluid (Nippongene, Tokyo, Japan) using a Tissue-ruptor (Qiagen, Valencia, CA, USA). Sample tissues were treated with chloroform, and RNA was precipitated in isopropanol. After a wash with 75% ethanol, the resulting total RNA was eluted in RNase-free water and stored at -80°C prior to use.
Reverse transcription (RT) and the synthesis of cDNA were performed using the PrimeScript RT reagent kit (Takara Biotechnology, Dalian, China), according to the manufacturer's instructions. Briefly, 2 μg of total RNA was mixed with PrimeScript buffer, Oligo dT primer, dNTP mix and PrimeScript RT Enzyme, and RNase-free water was added to make a total volume of 50 μl. The mixture was kept at 42°C for 50 min, and the reaction stopped at 70°C.
For RT-PCR, we used the Ex Taq Enzyme Hot Start PCR kit (Takara Biotechnology), according to the manufacturer's instructions. RT-PCR was carried out with 1 μl of RT product, which contains about 1 μg of cDNA, in a 50-μl reaction mixture containing sense and antisense primers, PCR buffer, dNTP mix, EX Taq Enzyme and RNase-free water, followed by preheating at 94°C for 2 min, denaturation 94°C for 30 sec, annealing for 40 sec and extension at 72°C for 1 min using the Takara PCR Thermal Cycler MP (Takara).
mRNA expression levels of MAO-A (GenBank Accession No. AK164457.1), MAO-B (GenBank Accession No. AK054050.1), DAT (GenBank Accession No. AF109391.1) and TH (GenBank Accession No. AK139568.1) were examined. The primers, cycle numbers and annealing temperature (°C) for reactions are listed in Table 1 . After RT-PCR, agarose gel (2%) electrophoresis was performed, and bands of RT-PCR prod-ucts were stained with ethidium bromide. The ratio of the intensity of each specific band to that of glyceraldehyde-3-phosphate dehydrogenase (GAPDH; GenBank Accession No. AK140794.1) was calculated. The PCR product size of MAO-A, MAO-B, DAT, TH and GAPDH were 637, 723 (Lam et al., 2004) , 541 (Xu et al., 2009) , 646 (Du et al., 2005) and 983 base pairs, respectively.
Protein extraction and Western blot analysis
For protein extraction, the cephalic parts of 2 to 3 embryos per dam, and the right half of the midbrain and striatum of the newborn and maternal brain were homogenized in 10 mM Tris-HCl buffer (pH 7.8) containing 150 mM NaCl, 1 mM EDTA, 1% NP-40, 10 mM NaF, 2 mM Na 3 VO 4 and the Proteinase Inhibitor Cocktail (Roche Applied Science, Penzberg, Germany) using the Tissue-ruptor (Qiagen), and centrifuged at 12,000 × g for 20 min at 4°C. Protein concentrations of the supernatant were determined with the Lowry protein assay kit (Bio-Rad, Hercules, CA, USA), according to the manufacturer's instructions. Extracted protein solutions were stored at -80°C until used.
Equal amounts of protein (30 μg) were mixed with the same volume of 5% melcaptoethanol in Laemmli Sample Buffer (Bio-Rad), and loaded onto a 10% SDS-PAGE gel, electrophoresed at 30 mA and transferred to a PVDF membrane (Bio-Rad) with an electric potential fo 25 V for 30-60 min. After treatment with Trisbuffered saline and 0.1% Tween-20 (TBST) with skim milk at room temperature for 1 hr, the membrane was probed with each of the following antibodies at 4°C for 18 hr; rabbit polyclonal anti-human MAO-A (sc-20156; Santa Cruz Biotechnology, Santa Cruz, CA, USA), goat polyclonal anti-mouse MAO-B (sc-18402; Santa cruz Biotechnology), rat anti-human DAT (MAB369; Millipore, Temecula, CA, USA), rabbit polyclonal antirat TH (AB152; Millipore) and rabbit anti-human β-actin (4967L; Cell Signaling Technology, Beverly, MA, USA) diluted in TBST with skim milk. After incubation with following appropriate secondary antibodies conjugated to horseradish peroxidase; donkey anti-rabbit IgG (NA934, GE Healthcare, Chalfont St Giles, UK), goat anti-rat IgG (NA935; GE Healthcare), and donkey anti-goat IgG (sc-2020; Santa cruz Biotechnology) diluted in TBST with skim milk at room temperature for 1 hr, positive immunoreactivity was visualized with the ECL Plus Western Blotting Detection Reagent (Amersham, Amersham, UK) for DAT and TH, or the ECL Prime Western Blotting Detection Reagent (Amersham) for MAO-A and MAO-B, and detected with the ChemDoc XRS-J (Bio-Rad). Conditions for the antibody reaction, the presence or absence of heating (94°C for 5 min) of proteins, concentrations of skim milk and dilutions of antibodies are shown in Table 2 . The ratio of the intensity of each specific band to that of β-actin was calculated.
High performance liquid chromatography-tandem mass spectrometry (LC/MS/MS)
For the LC/MS/MS analysis to measure dopamine, DOPAC and HVA concentrations, the midbrain and striatum from newborn mice were rapidly dissected on ice, weighed, frozen immediately at -80°C, and stored pri- Vol. 38 No. 3 or to analysis. The tissues were homogenized on ice with 9-fold amount (285-785 μl) of a 0.1% formic acid solution using a Shakemaster (bms, Tokyo, Japan). Fifty microliters of tissue homogenate was placed on a 96-well sample plate (2 ml size), followed by 50 μl of the 0.1% formic acid solution containing an internal standard. The samples were further diluted with 0.1% formic acid to a final volume of 300 μl. 
Measurements and statistics
All results were expressed as the mean ± standard error (S.E.). Statistical analyses were carried out with the F-test and Student's t-test to assess differences between data groups. Differences were considered significant when P < 0.05. 
RESULTS AND DISCUSSION
In the embryonic mice, the expression of DAT mRNA was decreased 6 to 24 hr after MPTP-or MPP + -treatment (Fig. 1a) , though the DAT protein was not detected (data not shown). A significant decrease in TH mRNA expression was observed 6 to 12 hr after MPTP-or MPP + -treatment (Fig. 1b) , and TH protein expression was also decreased at 12 hr (Fig. 2a) . No significant changes in MAO-A mRNA (Fig. 1c) and protein (Fig. 2b) expression were observed throughout the MPTP-or MPP + -treatment. No significant change in MAO-B mRNA (Fig. 1d ) expression was observed 6 to 24 hr after MPTP-or MPP + -treatment, but the MAO-B protein was detected in the embryonic brain, though a quantitative evaluation was impossible because of the faint expression (Fig. 2c) . DAT expression was not detected in the embryonic mice (data not shown).
In the midbrain of newborn mice, a decrease in DAT mRNA expression was observed 12 hr after treatment (MPTP or MPP + ), but it was not significant (Fig. 3a) . A decrease in DAT protein expression was observed 6 hr after treatment, and became significant at 12 hr, but the level had recovered at 24 hr (Fig. 4a) . A significant decrease in TH mRNA expression was observed 6 hr after treatment (Fig. 3b) , and a decrease in TH protein at 12 hr (Fig. 4b) . No significant changes to MAO-A mRNA (Fig. 3c) and protein (Fig. 4c ) levels were observed throughout treatment. No significant change in MAO-B mRNA expression (Fig. 3d) was observed either. The MAO-B protein was detected in the newborn midbrain, though a quantitative evaluation was impossible because of its faint expression, however, abundant expression was observed in the midbrain of maternal mice (Fig. 4d) . Significant decreases in dopamine and DOPAC levels were observed 6 to 12 hr after MPTP-treatment. The levels had generally recovered at 24 hr (Figs. 5a and b) . In contrast, no significant change in dopamine levels was observed from 6 to 24 hr in the MPP + -treated mice. A decrease in DOPAC was observed 6 to 12 hr after treatment. However, at 24 hr after MPP + -treatment, the DOPAC level was increased compared to that in control mice (Figs. 5a and  b) . The HVA level was unchanged throughout MPTP-or MPP + -treatment (Fig. 5c) .
In the striatum of newborn mice, a decrease of DAT mRNA expression was observed 6 hr after MPP + -treatment. The decrease became significant 12 hr after MPTPor MPP + -treatment, and the level had recovered at 24 hr (Fig. 6a) . A decrease in DAT protein expression was observed 6 hr after MPP + -treatment. The decrease became significant 12 hr after MPTP-or MPP + -treatment and 24 hr after MPTP-treatment (Fig. 7a) . A significant decrease in TH mRNA was observed 6 hr after MPTP-treatment, and a decrease was also observed 6 to 12 hr after MPP + -treatment (Fig. 6b) . A decrease in TH protein expression was observed 12 to 24 hr after MPTP-or MPP + -treatment, and that at 12 hr after MPP + -treatment was significant (Fig. 7b) . No significant changes in MAO-A mRNA (Fig. 6c) and protein (Fig. 7c) expression were observed throughout MPTP-or MPP + -treatment. No significant change in MAO-B mRNA expression (Fig. 6d) was observed 6 to 24 hr after MPTP-or MPP + -treatment. The MAO-B protein was detected in the newborn striatum, though a quantitative evaluation was impossible because of its faint expression, however, abundant expression was observed in the midbrain of maternal mice (Fig. 7d) . In the striatum of MPTP-treated mice, a decrease in the dopamine level at 12 hr, a significant decrease in the DOPAC level at 6 to 24 hr, and a significant decrease in the HVA level at 6 to 12 hr were observed (Figs. 8a, b and c). In contrast, in the striatum of MPP + -treated mice, dopamine and DOPAC levels were not changed (Figs. 8a and b), except for the DOPAC level at 24 hr, which was increased compared to that in control mice (Fig. 8b) . A slight decrease in the HVA level was observed 6 to 12 hr after MPP + -treatment. The level recovered at 24 hr (Fig.  8c) .
In the present study, a single injection of MPTP and MPP + reduced the levels of mRNAs and proteins of DAT and TH and the levels of dopamine and its metabolites, DOPAC and HVA, in the brain of embryonic and newborn mice as well. The recovery of those levels indicates that the neurotoxicity induced by a single injection of MPTP or MPP + is temporary and recoverable in embryonic and newborn mice.
As repeated MPTP-treatment causes damage in dopaminergic neurons similar to that seen in idiopathic PD, MPTP-treated mice represent an animal model for testing therapeutic materials for PD. Many previous studies suggest that prenatal exposure to MPTP induces a reduction of TH activity in the brain of newborn mice (Ochi et al., 1991; Ohya et al., 1990) . In one study (Freyaldenhoven et al., 1996) , a drastic decrease in DOPAC and HVA levels was observed 4 hr after the first MPTP-treatment, but the levels had generally recovered 24 hr after treatment. A similar time-course of change in DOPAC and HVA levels was observed after the second MPTP-treatment, though the levels were lower than after the first treatment. Five days after the third MPTPtreatment, DOPAC and HVA levels were still decreased. This study and the present study indicate that dopaminergic neurons can recover their activity reduced by a few times or acute MPTP-treatment, the neurons are severely injured by many times repeated or chronic MPTP-treatment. Other studies (Sugama et al., 2003; Ohashi et al., 2006) indicated that younger mice showed less damage to dopaminergic neurons after MPTP-treatment than older mice. We therefore assume that the early recovery of the dopaminergic neurons is due to the juvenility of embryos and newborns and a single, not multiple, injection of MPTP or MPP + .
The mRNA expression of TH in embryonic mice and of DAT and TH in the midbrain and striatum of newborn mice were decreased prior to the decrease of those proteins. These results are easily explained by the central dogma that the mRNA expression is the prior event to protein synthesis. Dopamine is biosynthesized from tyrosine by the TH enzyme, the time course of the changes in the TH protein expression and dopamine level is generally explained. However the dopamine level in the mid- brain was lower at 6 hr than at 12 hr, which conflicts with the change in TH protein expression. In the previous study (Ookubo et al., 2009; Freyaldenhoven et al., 1996) , dopamine and its metabolites, DOPAC and HVA, were significantly decreased at 4 or 5 hr after the injection of MPTP, though a decrease in TH protein expression was observed at 24 hr in the striatum of C57BL/6 mice. This sudden decrease in levels of dopamine, DOPAC and HVA preceding the decrease in TH protein expression likely reflects, in part, the decrease of dopaminergic neurons and TH activity, and the inhibition of MAO-B activity through the metabolism of MPTP to MPP + (Youngstar et al., 1989) . In the present study, the levels of mRNA and protein expression as well as the concentrations of dopamine and its metabolites were lower in the MPTP-treated embryonic and newborn mice than MPP + -treated mice. In our previous study (Sai et al., 2013) , the number of apoptotic cells in the brain was higher in the MPTP-treated mice than MPP + -treated mice. Therefore, we speculate that the difference in the decrease in mRNAs, proteins and dopamine and its metabolites between MPTP-and MPP + -treated mice may be caused by the dosages used in the present study, and higher-dose of MPP + -treatment may have caused more severe toxicity. Notably, the decrease in DOPAC levels in the MPTP-treated mice was much greater than that in the MPP + -treated mice in both the midbrain and the striatum. MAO-B activity is decreased through the metabolization of MPTP to MPP + (Hiebert et al., 1989) , and dopamine is converted to DOPAC also through MAO-B. The decreased MAO-B activity through the metabolization of MPTP may therefore induce the decreased DOPCA level in the brain of MPTP-treated mice.
In both the midbrain and striatum at 24 hr after the treatment, significantly higher levels of dopamine metabolites were observed in MPTP-or MPP + -treated mice compared to control ones. In the previous study (Freyaldenhoven et al., 1996) , a marked increase in DOPAC and HVA levels was observed at 24 hr after MPTP-treatment. The increase was thought to be related to an attempt to compensate for the loss of DA. Furthermore, the activity of catechol-O-methyl transferase (COMT), which converts DOPAC to HVA, may be involved in the increase in the DOPAC level.
In the present study, no significant gender difference was observed in any of the items evaluated (data not shown). Previous studies have showed gender differences in MPTP neurotoxicity in adult mice (Ookubo et al., 2009) , and suggested an influence of sex steroids, especially estrogen (Bourque et al., 2009; Dluzen et al., 1996) . However, 9-day-old newborn mice are still not mature, and no sex-related differences are observed in the brain at such an early postnatal period (Bourque et al., in press; Westberry and Wilson, 2012; Wilson et al., 2011) .
In conclusion, we revealed acute influences of MPTPor MPP + -treatment in the brain of embryonic (PD12) and newborn (9 days old) C57BL/6 mice. Single injections of MPTP and MPP + induced temporal and recoverable neurotoxic injury to embryonic and newborn mice. However, further studies are needed to examine the influence of MPTP-metabolizing enzyme, such as MAO-B.
